MovDisordV3, Main, Exploration, bibRecord, 004365

Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease

Identifieur interne : 004365 ( Main/Exploration ); précédent : 004364; suivant : 004366

Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease

Auteurs : Ruth Djaldetti [Israël] ; Rivkah Inzelberg [Israël] ; Nir Giladi [Israël] ; Amos D. Korczyn [Israël] ; Yehudit Peretz-Aharon [Israël] ; Martin J. Rabey [Israël] ; Yuval Herishano [Israël] ; Silvia Honigman [Israël] ; Sami Badarny [Israël] ; Eldad Melamed [Israël]

Source :

Movement Disorders [ 0885-3185 ] ; 2002-03.

RBID : ISTEX:B7619FEBD630121B2A45621BBC5D3F9C3B2A15C6

Descripteurs français

Pascal (Inist)
- Antiparkinsonien, Chimiothérapie, Fluctuation, Forme soluble, Homme, Lévodopa, Motricité, Parkinson maladie, Traitement, Voie orale.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Administration, Oral, Adult, Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Antiparkinson Agents (pharmacokinetics), Antiparkinson agent, Biological Availability, Carbidopa (administration & dosage), Carbidopa (adverse effects), Carbidopa (pharmacokinetics), Chemotherapy, Double-Blind Method, Drug Combinations, Female, Fluctuations, Human, Humans, LDEE, Levodopa, Levodopa (administration & dosage), Levodopa (adverse effects), Levodopa (analogs & derivatives), Levodopa (pharmacokinetics), Male, Middle Aged, Motricity, Neurologic Examination, Oral administration, Parkinson disease, Parkinson's disease, Soluble form, Treatment, Treatment Outcome, delayed‐on, no‐on.
MESH :
- chemical , administration & dosage : Antiparkinson Agents, Carbidopa, Levodopa.
- chemical , adverse effects : Antiparkinson Agents, Carbidopa, Levodopa.
- chemical , analogs & derivatives : Levodopa.
- chemical , pharmacokinetics : Antiparkinson Agents, Carbidopa, Levodopa.
- Administration, Oral, Adult, Aged, Biological Availability, Double-Blind Method, Drug Combinations, Female, Humans, Male, Middle Aged, Neurologic Examination, Treatment Outcome.

Abstract

Levodopa ethylester (LDEE), a highly soluble prodrug of levodopa, may overcome the impaired absorption of regular levodopa, due mainly to a combination of levodopa's poor solubility and delayed gastric emptying. We conducted a double‐blind, levodopa‐controlled, multicenter study of oral LDEE solution compared with standard levodopa–carbidopa (LD–CD) tablets. Sixty‐two patients with Parkinson's disease who had “delayed on” and “no‐on” subtypes of response fluctuations were randomly assigned for treatment with LDEE–CD or LD–CD 250/25 mg for 4 weeks (phase A). Only the first morning and first post‐lunch dose of LD were replaced. This was followed by a 2‐week extension with a supplementation of carbidopa (25 mg) to each replaced dose (phase B). Patients filled home diaries 2 weeks before and during the trial period in which times of turning on and off for the two doses were reported. In phase A, mean latency to turning on was reduced by 21% (morning dose) and 17% (post‐lunch dose) in the LDEE–CD group. Percentage of no‐on episodes after the post‐lunch dose was decreased by 21% in the LDEE–CD group but increased by 36% in the LD–CD group (P < 0.01). In phase B, LDEE–CD decreased latencies to on after the morning and post‐lunch doses and no‐on episodes after the post‐lunch dose. The beneficial effects of LDEE were supported by the pharmacokinetic data. Results indicate that LDEE solution is beneficial in ameliorating delayed on and no‐on response fluctuations. This effect of LDEE is due to more rapid levodopa absorption. © 2002 Movement Disorder Society.

Url:

https://api.istex.fr/document/B7619FEBD630121B2A45621BBC5D3F9C3B2A15C6/fulltext/pdf

DOI: 10.1002/mds.10075

Affiliations:

Israël

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease</title>
<author><name sortKey="Djaldetti, Ruth" sort="Djaldetti, Ruth" uniqKey="Djaldetti R" first="Ruth" last="Djaldetti">Ruth Djaldetti</name>
</author>
<author><name sortKey="Inzelberg, Rivkah" sort="Inzelberg, Rivkah" uniqKey="Inzelberg R" first="Rivkah" last="Inzelberg">Rivkah Inzelberg</name>
</author>
<author><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name>
</author>
<author><name sortKey="Korczyn, Amos D" sort="Korczyn, Amos D" uniqKey="Korczyn A" first="Amos D." last="Korczyn">Amos D. Korczyn</name>
</author>
<author><name sortKey="Peretz Haron, Yehudit" sort="Peretz Haron, Yehudit" uniqKey="Peretz Haron Y" first="Yehudit" last="Peretz-Aharon">Yehudit Peretz-Aharon</name>
</author>
<author><name sortKey="Rabey, Martin J" sort="Rabey, Martin J" uniqKey="Rabey M" first="Martin J." last="Rabey">Martin J. Rabey</name>
</author>
<author><name sortKey="Herishano, Yuval" sort="Herishano, Yuval" uniqKey="Herishano Y" first="Yuval" last="Herishano">Yuval Herishano</name>
</author>
<author><name sortKey="Honigman, Silvia" sort="Honigman, Silvia" uniqKey="Honigman S" first="Silvia" last="Honigman">Silvia Honigman</name>
</author>
<author><name sortKey="Badarny, Sami" sort="Badarny, Sami" uniqKey="Badarny S" first="Sami" last="Badarny">Sami Badarny</name>
</author>
<author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:B7619FEBD630121B2A45621BBC5D3F9C3B2A15C6</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1002/mds.10075</idno>
<idno type="url">https://api.istex.fr/document/B7619FEBD630121B2A45621BBC5D3F9C3B2A15C6/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000418</idno>
<idno type="wicri:Area/Istex/Curation">000418</idno>
<idno type="wicri:Area/Istex/Checkpoint">002C56</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Djaldetti R:oral:solution:of</idno>
<idno type="wicri:Area/Main/Merge">006370</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:02-0309334</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002793</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000528</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002671</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Djaldetti R:oral:solution:of</idno>
<idno type="wicri:Area/Main/Merge">006710</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:11921115</idno>
<idno type="wicri:Area/PubMed/Corpus">003B30</idno>
<idno type="wicri:Area/PubMed/Curation">003B30</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003A01</idno>
<idno type="wicri:Area/Ncbi/Merge">000721</idno>
<idno type="wicri:Area/Ncbi/Curation">000721</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000721</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Djaldetti R:oral:solution:of</idno>
<idno type="wicri:Area/Main/Merge">006152</idno>
<idno type="wicri:Area/Main/Curation">004365</idno>
<idno type="wicri:Area/Main/Exploration">004365</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease</title>
<author><name sortKey="Djaldetti, Ruth" sort="Djaldetti, Ruth" uniqKey="Djaldetti R" first="Ruth" last="Djaldetti">Ruth Djaldetti</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Neurology, Rabin Medical Center, Petah Tiqva</wicri:regionArea>
<wicri:noRegion>Petah Tiqva</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Inzelberg, Rivkah" sort="Inzelberg, Rivkah" uniqKey="Inzelberg R" first="Rivkah" last="Inzelberg">Rivkah Inzelberg</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Hillel Yaffe Medical Center, Hadera</wicri:regionArea>
<wicri:noRegion>Hadera</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Sourasky Medical Center, Tel Aviv</wicri:regionArea>
<wicri:noRegion>Tel Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Korczyn, Amos D" sort="Korczyn, Amos D" uniqKey="Korczyn A" first="Amos D." last="Korczyn">Amos D. Korczyn</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Sourasky Medical Center, Tel Aviv</wicri:regionArea>
<wicri:noRegion>Tel Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Peretz Haron, Yehudit" sort="Peretz Haron, Yehudit" uniqKey="Peretz Haron Y" first="Yehudit" last="Peretz-Aharon">Yehudit Peretz-Aharon</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Rambam Medical Center, Haifa</wicri:regionArea>
<wicri:noRegion>Haifa</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rabey, Martin J" sort="Rabey, Martin J" uniqKey="Rabey M" first="Martin J." last="Rabey">Martin J. Rabey</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Assaf‐Harofeh Hospital, Zerifin</wicri:regionArea>
<wicri:noRegion>Zerifin</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Herishano, Yuval" sort="Herishano, Yuval" uniqKey="Herishano Y" first="Yuval" last="Herishano">Yuval Herishano</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Soroka Medical Center, Beer Sheva</wicri:regionArea>
<wicri:noRegion>Beer Sheva</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Honigman, Silvia" sort="Honigman, Silvia" uniqKey="Honigman S" first="Silvia" last="Honigman">Silvia Honigman</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>HaCarmel Hospital, Haifa</wicri:regionArea>
<wicri:noRegion>Haifa</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Badarny, Sami" sort="Badarny, Sami" uniqKey="Badarny S" first="Sami" last="Badarny">Sami Badarny</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>HaCarmel Hospital, Haifa</wicri:regionArea>
<wicri:noRegion>Haifa</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Neurology, Rabin Medical Center, Petah Tiqva</wicri:regionArea>
<wicri:noRegion>Petah Tiqva</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2002-03">2002-03</date>
<biblScope unit="vol">17</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="297">297</biblScope>
<biblScope unit="page" to="302">302</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">B7619FEBD630121B2A45621BBC5D3F9C3B2A15C6</idno>
<idno type="DOI">10.1002/mds.10075</idno>
<idno type="ArticleID">MDS10075</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term>
<term>Adult</term>
<term>Aged</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (pharmacokinetics)</term>
<term>Antiparkinson agent</term>
<term>Biological Availability</term>
<term>Carbidopa (administration & dosage)</term>
<term>Carbidopa (adverse effects)</term>
<term>Carbidopa (pharmacokinetics)</term>
<term>Chemotherapy</term>
<term>Double-Blind Method</term>
<term>Drug Combinations</term>
<term>Female</term>
<term>Fluctuations</term>
<term>Human</term>
<term>Humans</term>
<term>LDEE</term>
<term>Levodopa</term>
<term>Levodopa (administration & dosage)</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (analogs & derivatives)</term>
<term>Levodopa (pharmacokinetics)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Motricity</term>
<term>Neurologic Examination</term>
<term>Oral administration</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Soluble form</term>
<term>Treatment</term>
<term>Treatment Outcome</term>
<term>delayed‐on</term>
<term>no‐on</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Carbidopa</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Carbidopa</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Carbidopa</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term>
<term>Adult</term>
<term>Aged</term>
<term>Biological Availability</term>
<term>Double-Blind Method</term>
<term>Drug Combinations</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neurologic Examination</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term>
<term>Chimiothérapie</term>
<term>Fluctuation</term>
<term>Forme soluble</term>
<term>Homme</term>
<term>Lévodopa</term>
<term>Motricité</term>
<term>Parkinson maladie</term>
<term>Traitement</term>
<term>Voie orale</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Levodopa ethylester (LDEE), a highly soluble prodrug of levodopa, may overcome the impaired absorption of regular levodopa, due mainly to a combination of levodopa's poor solubility and delayed gastric emptying. We conducted a double‐blind, levodopa‐controlled, multicenter study of oral LDEE solution compared with standard levodopa–carbidopa (LD–CD) tablets. Sixty‐two patients with Parkinson's disease who had “delayed on” and “no‐on” subtypes of response fluctuations were randomly assigned for treatment with LDEE–CD or LD–CD 250/25 mg for 4 weeks (phase A). Only the first morning and first post‐lunch dose of LD were replaced. This was followed by a 2‐week extension with a supplementation of carbidopa (25 mg) to each replaced dose (phase B). Patients filled home diaries 2 weeks before and during the trial period in which times of turning on and off for the two doses were reported. In phase A, mean latency to turning on was reduced by 21% (morning dose) and 17% (post‐lunch dose) in the LDEE–CD group. Percentage of no‐on episodes after the post‐lunch dose was decreased by 21% in the LDEE–CD group but increased by 36% in the LD–CD group (P < 0.01). In phase B, LDEE–CD decreased latencies to on after the morning and post‐lunch doses and no‐on episodes after the post‐lunch dose. The beneficial effects of LDEE were supported by the pharmacokinetic data. Results indicate that LDEE solution is beneficial in ameliorating delayed on and no‐on response fluctuations. This effect of LDEE is due to more rapid levodopa absorption. © 2002 Movement Disorder Society.</div>
</front>
</TEI>
<affiliations><list><country><li>Israël</li>
</country>
</list>
<tree><country name="Israël"><noRegion><name sortKey="Djaldetti, Ruth" sort="Djaldetti, Ruth" uniqKey="Djaldetti R" first="Ruth" last="Djaldetti">Ruth Djaldetti</name>
</noRegion>
<name sortKey="Badarny, Sami" sort="Badarny, Sami" uniqKey="Badarny S" first="Sami" last="Badarny">Sami Badarny</name>
<name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name>
<name sortKey="Herishano, Yuval" sort="Herishano, Yuval" uniqKey="Herishano Y" first="Yuval" last="Herishano">Yuval Herishano</name>
<name sortKey="Honigman, Silvia" sort="Honigman, Silvia" uniqKey="Honigman S" first="Silvia" last="Honigman">Silvia Honigman</name>
<name sortKey="Inzelberg, Rivkah" sort="Inzelberg, Rivkah" uniqKey="Inzelberg R" first="Rivkah" last="Inzelberg">Rivkah Inzelberg</name>
<name sortKey="Korczyn, Amos D" sort="Korczyn, Amos D" uniqKey="Korczyn A" first="Amos D." last="Korczyn">Amos D. Korczyn</name>
<name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name>
<name sortKey="Peretz Haron, Yehudit" sort="Peretz Haron, Yehudit" uniqKey="Peretz Haron Y" first="Yehudit" last="Peretz-Aharon">Yehudit Peretz-Aharon</name>
<name sortKey="Rabey, Martin J" sort="Rabey, Martin J" uniqKey="Rabey M" first="Martin J." last="Rabey">Martin J. Rabey</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004365 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004365 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:B7619FEBD630121B2A45621BBC5D3F9C3B2A15C6
   |texte=   Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease

Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.